Non-invasive detection kit for early diagnosis of Alzheimer's disease
Invention Disclosure · 2022
DOI: 10.1016/j.inv.2022.100004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Invention Disclosure, 2022. Verfasst von Wing Ho Chau und 3 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Demenz
Abstract (Originalsprache)
The present invention discloses a new Alzheimer's disease (AD) diagnostic kit that tests blood, saliva and urine, providing a faster, more sensitive, affordable and non-invasive way than conventional method of detection. This detection assay only requires a few microliters of the body fluids to quantify the target AD-related protein biomarkers. The assay is based on the immunoreaction between the target protein biomarkers and their corresponding pair of antibodies followed by fluorescence labelling with a newly developed cyanine turn-on fluorophore. The intensity of the fluorescence signal can act as an index to evaluate the severity of AD. Therefore, the present invention can serve as an analytical tool for early diagnosis, progression monitoring and staging.
Zitieren
APA
Chau, W. H., Cheung, C. Y., Li, H. W., & Wong, M. S. (2022). Non-invasive detection kit for early diagnosis of Alzheimer's disease. Invention Disclosure. https://doi.org/10.1016/j.inv.2022.100004
Vancouver
Chau WH, Cheung CY, Li HW, Wong MS. Non-invasive detection kit for early diagnosis of Alzheimer's disease. Invention Disclosure. 2022. doi:10.1016/j.inv.2022.100004
BibTeX
@article{Chau2022,
author = {Chau, Wing Ho and Cheung, Chung Yan and Li, Hung Wing and Wong, Man Shing},
title = {Non-invasive detection kit for early diagnosis of Alzheimer's disease},
journal = {Invention Disclosure},
year = {2022},
doi = {10.1016/j.inv.2022.100004}
}
EUVIMED